Legal and Recreational Sales of Cannabis Products Expected to Show Continued Growth

Friday, December 29, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, December 29, 2017 /PRNewswire/ --

According to data provided

by New Frontier Data, in partnership with Arcview Market Research, the legalization of cannabis in California, Massachusetts, Nevada, Florida,
Arkansas and North Dakota will result in new markets that account for $7.1 billion in sales by 2020. The research estimates that the overall U.S. cannabis market will exceed $20.9 billion by 2020. Nevada presents significant opportunities for investors and businesses in the legal cannabis market. New Frontier Data explains that Nevada ranks as a top tourism destination, due to generous patient reciprocity laws, and the allowance for medical cannabis businesses to be formed as for-profit enterprises are all important factors expected to boost the industry. The combined medical and adult use sales in Nevada are expected to reach about $622 million by 2020. Pivot Pharmaceticals Inc. (OTC: PVOTF), Lexaria Bioscience Corp. (OTC: LXRP), Vitality Biopharma, Inc. (OTC: VBIO), Kush Bottles, Inc. (OTC: KSHB), General Cannabis Corp. (OTC: CANN)

New Frontier Data Founder & CEO Giadha DeCarcer, said, "The passage of Nevada's adult use legalization measure opens the floodgates for America's adult playground. As the most sophisticated hospitality destination in the country drawing an estimated 55 million visitors in 2016 alone, the integration of cannabis into Nevada's economy will create an opportunity for canna-tourism on a scale not seen before in the country."

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) also listed on the Canadian Stock Exchange under the Ticker 'PVOT'. The company just announced breaking news this morning that, "It has commenced development of PGS-N001, a 1% Oral Cannabidiol (CBD) improved solubilisate product with its German technology partner SolMic GmbH. Pivot previously announced the licensing of worldwide rights for SolMic Technology in the field of cannabinoids and has now initiated the next stage of the agreement to complete formulation, development, testing and manufacturing in preparation for launch in legalized cannabis markets in 2018. PGS-N001 is a bio-cannabis product. It will be formulated and developed to treat a variety of indications such as the treatment of Chemo-Induced Nausea & Vomiting (CINV), a major therapeutic problem in the Cancer Supportive Care area."

According to published data, "the global medical marijuana market is expected to reach a value of US $55.8 billion by 2025", according to a report by Grand View Research Inc. "Several states have approved the use of cannabis in medical applications such as chemotherapies and pain management. The growing number of states and countries getting approval for using cannabis in therapeutic applications is one of the crucial factors driving the demand over the coming few years."

Dr. Wolfgang Schoenfeld, SolMic GmbH's Chief Executive Officer, states that "I am very pleased to continue to work with the Pivot Pharmaceuticals team to develop novel cannabinoid products and therapies using our proprietary SolMic formulation technology. Our technology strongly enhances bioavailability of cannabinoids and improves product attributes such as stability, odour and masks unpleasant tastes, thus making it a better product experience for patients and consumers."

Dr. Patrick Frankham, Pivot's Chief Executive Officer, states that "following our technology portfolio review meeting held in Montreal, Canada, we decided to advance this asset from our pipeline in order to have a world class bio-cannabinoid product containing CBD isolate available for commercialization in 2018. The selection of PGS-N001 will target markets where there is an existing framework for approved use of the drug in medical applications."

Lexaria Bioscience Corp. (OTCQB: LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Recently, the company announced the United States Patent and Trademark Office ("USPTO") has granted patent number 9,839,612 B2 for the use of DehydraTECHTM technology as a delivery platform for a wide variety of Active Pharmaceutical Ingredients ("APIs") including all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications ("NSAIDs"); and nicotine. "Lexaria has now locked-up the IP for its next-generation drug delivery system" said Chief Executive Officer Chris Bunka. "This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market." Vitality Biopharma, Inc. (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. On November 1, 2017, the company announced completion of pivotal manufacturing agreements that enable the production of clinical-grade cannabinoid pharmaceuticals at its R&D facilities in California. In early 2017, after receiving approval from the U.S. DEA for its cannabinoid pharmaceutical research, Vitality contracted with a research services provider to obtain new software and protocols to support its internal manufacturing team and to ensure GMP manufacturing compliance. The Company has implemented these protocols for initial production of cannabosides, the company's cannabinoid prodrugs that are designed to target the gastrointestinal tract and thereby avoid the intoxicating side effects of THC. Vitality has also recently entered into a services agreement with a specialist analytical chemistry firm, in order to provide independent verification of the Company's analytical procedures and batch release testing, in compliance with FDA and international regulatory standards. Kush Bottles, Inc. (OTCQB: KSHB) is a dynamic sales platform that provides unique products and services for both businesses and consumers in the cannabis industry. On November 28, 2017, the company reported financial results for its fiscal year ended August 31, 2017. Revenue was up 129% Year-over-Year to $18.8 million; revenues included four months of sales from CMP Wellness which was acquired on May 1, 2017. Net income, including $943,000 in non-cash stock compensation, $301,000 in depreciation and amortization expense and $4.6 million in SG&A, was $69,000 compared to net income of $72,000 in fiscal year 2016; the increase in operating expenses stems from costs associated with the acquisition of CMP Wellness, as well as higher SG&A costs to support an expanded outside sales program. General Cannabis Corp. (OTCQB: CANN) is the comprehensive national resource for the highest-quality service providers available to the regulated cannabis industry. On December 21, 2017, the company announced it signed a $955,000 two-year contract today to manage a grow facility in California. This represents the largest single contract the company has undertaken since inception.  The Company also plans to provide significant other services, including hardware and supply procurement, in addition to the initial contract terms. "We have been developing potential clients in California for the past year, where cannabis becomes legalized for adult use on Jan. 1, 2018," said Robert Frichtel, CEO of General Cannabis. "California will become the world's largest legalized and regulated cannabis market at the beginning of the new year.  We are pleased to have gained a solid foothold in what is projected to be a $7 billion state-wide market."

Subscribe Now! Watch us report from LIVE https://www.youtube.com/FinancialBuzzMedia Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, FinancialBuzz.com has been compensated five thousand dollars for financial news dissemination and PR services by vintage capital group inc. for pivot pharmaceuticals inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com .

Media Contact: info@financialbuzz.com +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store